Abstract Interleukin-12 (IL-12) and interleukin-23 (IL-23), which belong to the IL-12 family of
cytokines, have a key role in intestinal homeostasis and inflammation and are implicated in …

(1) Background: Evidence on the outcomes of ustekinumab treatment in real-world Crohn's
disease (CD) patients is needed. Our aim was to evaluate the effectiveness and safety of …

The treatment of patients with moderate to severe Crohn's disease [CD] is still challenging.
Therapeutic options include steroids, immunosuppressants, anti-TNFα agents, vedolizumab …

Abstract Background and Aims Clinical trials and real-life studies with ustekinumab in
Crohn's disease [CD] have revealed a good efficacy and safety profile. However, these data …

Background Anti-tumour necrosis factor (anti-TNF) agents are associated with increased
infection risk among elderly inflammatory bowel disease (IBD) patients, and thus, alternative …

Abstract The burden of Inflammatory Bowel Disease (IBD) is increasing worldwide, with a
particular increase in the prevalence in the elderly population, due to the ageing of young …

As our comprehension of the pathogenic mechanisms of inflammatory bowel disease (IBD)
increases, the therapeutic armamentarium for its treatment can expand, and novel target …

Abstract Background and Aim: Newer biologics appeared safer in landmark clinical trials,
but their safety is understudied in vulnerable populations. The aim of the present study was …

Background: Ustekinumab (UST) is an IL12/23 inhibitor utilized for altering inflammatory
responses in inflammatory bowel disease (IBD). Clinical trials and case reports suggested …

Approximately one out of every 88 seniors has inflammatory bowel disease (IBD), and this is
expected to increase in the future. They are more likely to have left-sided disease in …